Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
-
16261
-
16262
-
16263
-
16264
Impact on Patients’ Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial
Published 2015“…However, the overall TB-attributed death rate was lower in the intervention arm (2.3% vs. 3.8%). Adjusted for HIV status, age group and city, the intervention resulted in a 35% decrease in TB-attributed deaths (OR=0.65, 95%CI=0.44-0.97).…”
-
16265
-
16266
-
16267
HE images of the adherent cells in the 2D and 3D scaffold systems.
Published 2024“…Instead, in SHR1 (5x magnification), SHR2 and SHR3 (10x magnification) the cells barely reached 50% confluence at 72h, then the cellularity decreased between 72h and 7 days (j-o). 2D culture (5x magnification) show a higher cellularity in each time point compared to scaffolds (a-c). …”
-
16268
Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
Published 2018“…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
-
16269
Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
Published 2018“…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
-
16270
Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
Published 2018“…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
-
16271
Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
Published 2018“…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
-
16272
-
16273
-
16274
Bald thigh syndrome in sighthounds—Revisiting the cause of a well-known disease
Published 2019“…Further research is required to clarify whether the <i>IGFBP5</i> variant represents a predisposing genetic risk factor. …”
-
16275
-
16276
Stress-sensitive antidepressant-like effects of ketamine in the mouse forced swim test
Published 2019“…This combination of fast action and a therapeutic effect that lasts far beyond the drug’s half-life points to a unique mechanism of action. …”
-
16277
Synthesis, Crystal Structure, and Spectroscopic Characterization of a Series of Cubane-like Mo−Sb Clusters Containing a [Mo<sub>3</sub>SbOS<sub>3</sub>]<sup>7+</sup> Core
Published 1999“…Crystal data: <b>1</b>, triclinic, <i>P</i>-1, <i>a</i> = 11.746(4) Å, <i>b</i> = 12.462(3) Å, <i>c</i> = 17.851(6) Å, α = 73.54(2)°, β = 75.06(3)°, γ = 88.11(3)°, <i>V</i> = 2419(3) Å<sup>3</sup>, <i>Z</i> = 2, 4253 reflections, <i>R</i> = 0.055; <b>2</b>, triclinic, <i>P</i>-1, <i>a</i> = 12.76(1) Å, <i>b</i> = 17.86(1) Å, <i>c</i> = 11.882(4) Å, α = 75.05(4)°, β = 88.15(7)°, γ = 73.24(4)°, <i>V</i> = 2502(6) Å<sup>3</sup>, <i>Z</i> = 2, 1849 reflections, <i>R</i> = 0.086; <b>3</b>, triclinic, <i>P</i>-1, <i>a</i> = 11.727(4) Å, <i>b</i> = 12.951(3) Å, <i>c</i> = 17.957(4) Å, α = 73.52(3)°, β = 76.22(3)°, γ = 89.00(2)°, <i>V</i> = 2536(3) Å<sup>3</sup>, <i>Z</i> = 2, 6306 reflections, <i>R</i> = 0.053; <b>5</b>, triclinic, <i>P</i>-1, <i>a</i> = 13.261(4) Å, <i>b</i> = 13.529(4) Å, <i>c</i> = 12.535(8) Å, α = 101.54(3)°, β = 105.13(4)°, γ = 93.20(2)°, <i>V</i> = 2113(2) Å<sup>3</sup>, <i>Z</i> = 2, 4104 reflections, <i>R</i> = 0.060.…”
-
16278
-
16279
-
16280
NaSal failed to increase excitability of 5-HTergic neurons in the absence of the GABAergic inhibition in the DRN of the ChR2 transgenic mouse.
Published 2015“…(B) Sample recordings from a 5-HTergic neuron showing that NaSal decreased voltage responses to a series of hyperpolarizing currents (-10 to -60 pA, -10 pA/step, duration: 500 ms). …”